Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trialSilvio Danese, Wit Danilkiewicz, Brian G. Feagan et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 72